Search company, investor...

Incept Biosystems

inceptbio.com

Founded Year

2005

Stage

Acquired | Acquired

Total Raised

$3.33M

About Incept Biosystems

Incept BioSystems aims to develop nanoscale technologies that provide cell biologists the ability to obtain high value data about cell growth and behavior. Their technologies were developed to improve the in vitro manipulation, performance and viability for Premium Cell Management applications. On January 12, 2011, Incept BioSystems was acquired by ORIGIO. The terms of the transaction were not disclosed.

Headquarters Location

401 West Morgan Road

Ann Arbor, Michigan, 48108,

United States

Missing: Incept Biosystems's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Incept Biosystems's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Incept Biosystems

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Incept Biosystems is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Incept Biosystems Patents

Incept Biosystems has filed 97 patents.

The 3 most popular patent topics include:

  • Medical equipment
  • Vascular diseases
  • Dosage forms
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/12/2016

6/28/2022

Dosage forms, Drug delivery devices, Glucocorticoids, Diseases of the eye and adnexa, Pregnanes

Grant

Application Date

5/12/2016

Grant Date

6/28/2022

Title

Related Topics

Dosage forms, Drug delivery devices, Glucocorticoids, Diseases of the eye and adnexa, Pregnanes

Status

Grant

Incept Biosystems Frequently Asked Questions (FAQ)

  • When was Incept Biosystems founded?

    Incept Biosystems was founded in 2005.

  • Where is Incept Biosystems's headquarters?

    Incept Biosystems's headquarters is located at 401 West Morgan Road, Ann Arbor.

  • What is Incept Biosystems's latest funding round?

    Incept Biosystems's latest funding round is Acquired.

  • How much did Incept Biosystems raise?

    Incept Biosystems raised a total of $3.33M.

  • Who are the investors of Incept Biosystems?

    Investors of Incept Biosystems include ORIGIO, Grand Angels, Venture Investors, Plymouth Growth Partners and Angel Healthcare Investors.

  • Who are Incept Biosystems's competitors?

    Competitors of Incept Biosystems include InvivoSciences, Amnis Corporation, Aileron Therapeutics, WaferGen Bio-systems, Inotek Pharmaceuticals and 12 more.

Compare Incept Biosystems to Competitors

e
eSionic

eSionic, formerly Zettacore, enables devices and systems that consume less materials, generate less waste, have longer life, operate with higher reliability, use less energy, integrate seamlessly, operate more efficiently and cost less.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

G
Gahaga Biosciences

Gahaga Biosciences was founded in 2006 to commercialize a method for the isolation of stem cells from placental and umbilical tissues to be used in basic research. Gahaga Biosciences intends to provide stem cells to the research and commercial markets which are valued as a potential source of a range of types of tissue. Many scientists say embryonic stem cells are generally more versatile than adult cells, although they continue to explore the possibilities of adult stem cells. The company believe that placental and umbilical stems cells are an ideal model system for conducting basic research on cell differentiation and regulation. Gahaga Biosciences seeks to supply researchers with materials to focus on the basic mechanisms of stem cell differentiation - how stem cells make the decision to move from their stem cell state into a more committed phenotype. Gahaga also seeks to exploit the company's experience in other methods such as pancreatic islets.

I
Innovate Technologies In Biological System

Innoprot tGFP-BACE1 HEK293 Cell Line CB2 Internalization Assay Cell Line hGR Nuclear Translocation Assay Cell Line Human Cardiac Myocytes Assay Development Neurotoxicity Assay induced by beta amyloid NEWS Innoprot has been awarded on the Bizkaia Ekinez Prizes 05/06/2009 Innoprot has been awarded on the Bizkaia Ekinez Prizes with the "Gaztedi Prize"

I
InvivoSciences

Invivo Sciences technology aims to bridge the gap in preclinical research performed using animal models and cell culture systems. Per the company, the advances in lab-automation coupled with the company's expertise in tissue engineering allows InvivoSciences to commercialize fast, reliable, and cost effective screening systems.

N
Narvalus srl

The firm aims to provide powerful tools based on microelectronic technology to scientists involved in basic molecular biology research. Investigating the biological actions of molecules "in vitro" on cultured cells is a fundamental step for drug development and for basic life sciences. Routine techniques for intracellular delivery are high-cost and time-consuming procedures involving the use of a large amount of the candidate molecule and a stochastic interpretation of the results. Thanks to an combination of cell and molecular biology with semiconductor technology the company developed a new technique overcoming these limitations.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.